These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1095 related articles for article (PubMed ID: 32603972)

  • 101. The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study.
    Wei H; Kong M; Zhang C; Guan L; Ba M;
    Quant Imaging Med Surg; 2018 Nov; 8(10):1004-1019. PubMed ID: 30598878
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study.
    Song R; Wu X; Liu H; Guo D; Tang L; Zhang W; Feng J; Li C
    Korean J Radiol; 2022 Jan; 23(1):89-100. PubMed ID: 34983097
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
    Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.
    Sagare AP; Deane R; Zetterberg H; Wallin A; Blennow K; Zlokovic BV
    J Alzheimers Dis; 2011; 24(1):25-34. PubMed ID: 21157031
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
    Frankfort SV; Tulner LR; van Campen JP; Verbeek MM; Jansen RW; Beijnen JH
    Curr Clin Pharmacol; 2008 May; 3(2):123-31. PubMed ID: 18700307
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer's Disease.
    Wen Q; Wittens MMJ; Engelborghs S; van Herwijnen MHM; Tsamou M; Roggen E; Smeets B; Krauskopf J; Briedé JJ
    ACS Chem Neurosci; 2024 Mar; 15(5):1042-1054. PubMed ID: 38407050
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
    Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R
    Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition.
    Leow AD; Yanovsky I; Parikshak N; Hua X; Lee S; Toga AW; Jack CR; Bernstein MA; Britson PJ; Gunter JL; Ward CP; Borowski B; Shaw LM; Trojanowski JQ; Fleisher AS; Harvey D; Kornak J; Schuff N; Alexander GE; Weiner MW; Thompson PM;
    Neuroimage; 2009 Apr; 45(3):645-55. PubMed ID: 19280686
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Biomarkers for predicting cognitive decline in those with normal cognition.
    Steenland K; Zhao L; Goldstein F; Cellar J; Lah J
    J Alzheimers Dis; 2014; 40(3):587-94. PubMed ID: 24496071
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment.
    Cicognola C; Janelidze S; Hertze J; Zetterberg H; Blennow K; Mattsson-Carlgren N; Hansson O
    Alzheimers Res Ther; 2021 Mar; 13(1):68. PubMed ID: 33773595
    [TBL] [Abstract][Full Text] [Related]  

  • 113. A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non-converter Alzheimer's disease subjects with consideration for their amyloid beta status.
    Morar U; Izquierdo W; Martin H; Forouzannezhad P; Zarafshan E; Unger E; Bursac Z; Cabrerizo M; Barreto A; Vaillancourt DE; DeKosky ST; Loewenstein D; Duara R; Adjouadi M
    Alzheimers Dement (Amst); 2022; 14(1):e12258. PubMed ID: 35229014
    [TBL] [Abstract][Full Text] [Related]  

  • 114. P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders.
    Ma LZ; Hu H; Wang ZT; Ou YN; Dong Q; Tan L; Yu JT
    Alzheimers Res Ther; 2021 Dec; 13(1):200. PubMed ID: 34911582
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Baseline Neurodegeneration Influences the Longitudinal Effects of Tau on Cognition.
    Ng KP; Cheng GH; Yatawara C; Rosa-Neto P; Gauthier S; Kandiah N;
    J Alzheimers Dis; 2021; 82(1):159-167. PubMed ID: 33998536
    [TBL] [Abstract][Full Text] [Related]  

  • 116. The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.
    Kim H; Levine A; Cohen D; Gehrman P; Zhu X; Devanand DP; Lee S; Goldberg TE;
    J Alzheimers Dis; 2022; 87(4):1567-1580. PubMed ID: 35491776
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
    Dickerson BC; Wolk DA;
    Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.
    Liu W; Lin H; He X; Chen L; Dai Y; Jia W; Xue X; Tao J; Chen L
    Transl Psychiatry; 2020 Apr; 10(1):125. PubMed ID: 32350238
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
    J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework.
    Xiong X; He H; Ye Q; Qian S; Zhou S; Feng F; Fang EF; Xie C
    CNS Neurosci Ther; 2024 Feb; 30(2):e14357. PubMed ID: 37438991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.